Acetyl octapeptide-3 is a synthetic eight-amino-acid peptide used as a cosmetic ingredient and best known under the trade name SNAP-8. This guide covers its structure, its proposed mechanism, the published studies and its regulatory status. Sources were checked on November 17, 2026.
Quick answer: Acetyl octapeptide-3 (SNAP-8) is a lab-made peptide that extends the Argireline sequence by two amino acids. It is a cosmetic ingredient, not a drug, and it has no FDA approval. Its claimed mechanism, mimicking the nerve protein SNAP-25, rests mainly on manufacturer data. We found no Cosmetic Ingredient Review safety assessment for it.
Vitrapep does not sell acetyl octapeptide-3; this page is a reference summary of published research and regulatory information.
What is acetyl octapeptide-3?
Acetyl octapeptide-3 is an INCI name, the standard name used on cosmetic ingredient lists. CosIng, the European Commission’s cosmetic ingredient database, describes it as “the reaction product of acetic acid and Octapeptide-3” (CosIng, 2026). In plain terms, it is a chain of eight amino acids with an acetyl cap on one end.
PubChem gives the sequence as Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. It lists the formula as C41H70N16O16S and the molecular weight as 1,075.2 g/mol (PubChem CID 76283482). The first six residues match acetyl hexapeptide-8, sold as Argireline, which PubChem lists as Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (PubChem CID 71587772). Acetyl octapeptide-3 adds alanine and aspartic acid. Our Argireline guide covers the shorter peptide, and our peptide primer explains the basics.
A 2020 review gives the same sequence for SNAP-8 and credits the name to Lipotec (Errante et al., 2020). Lubrizol now markets SNAP-8 peptide solution C as an octapeptide ingredient (Lubrizol). PubChem also lists the name acetyl glutamyl heptapeptide-3. CosIng returned no entry under that name.
Acetyl octapeptide-3: key facts
| Fact | Detail |
|---|---|
| INCI name | Acetyl Octapeptide-3 |
| Structure type | Linear synthetic peptide; eight amino acids with an acetylated start and an amide end |
| Sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 |
| Molecular formula | C41H70N16O16S |
| Molecular weight | 1,075.2 g/mol |
| Main cosmetic function (CosIng) | Humectant; skin conditioning |
| Trade name(s) | SNAP-8 (Lipotec name; sold by Lubrizol) |
How does acetyl octapeptide-3 work?
The proposed mechanism involves SNARE, a protein complex that lets nerve endings release chemical messengers. SNAP-25 is one of its core proteins. Citing Lipotec, Errante and colleagues describe SNAP-8 as mimicking SNAP-25 and acting “as a competitive inhibitor” of complex assembly. In the company’s assay, SNAP-8 reduced glutamate release by up to 43% (Errante et al., 2020).
In this model, less messenger is released and muscle contraction weakens. The supporting data come from company material cited in the review, not from independent peer-reviewed experiments. Compare the shorter Argireline, which was proposed to work the same way.
Skin entry is a separate question. A 2026 review notes that cosmetic peptides have historically weighed under 500 Da, “likely to improve penetration into the skin” (Bjerke et al., 2026). At 1,075.2 g/mol, acetyl octapeptide-3 is about twice that size.
What is acetyl octapeptide-3 used for?
CosIng lists two cosmetic functions for acetyl octapeptide-3: humectant and skin conditioning. A humectant helps a product hold water. A skin-conditioning agent helps keep skin in good condition. The CosIng record links no annex of the EU Cosmetics Regulation and no scientific committee opinion to this ingredient.
Lubrizol describes SNAP-8 as an “octapeptide that minimizes the appearance of persistent expression wrinkles caused by facial muscle contractions” (Lubrizol). That is a manufacturer claim about appearance, not an FDA finding. A 2026 review groups acetyl octapeptide-3 with neurotransmitter-inhibiting cosmetic peptides (Bjerke et al., 2026). For other cosmetic peptide classes, see our peptides in skincare overview.
What does the research show?
Manufacturer data. Errante and colleagues, citing Lipotec, report a mean wrinkle-depth reduction of 35% in the company’s test, with a maximum of 62%. The review cites company material rather than a peer-reviewed trial, so the study design cannot be checked.
Avcil 2020 (human, no control group). This single-center study tested hyaluronic acid microneedle patches. The patches held acetyl octapeptide-3, an arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts. After 12 weeks, the authors reported 25.8% fewer fine lines and wrinkles and 15.4% better hydration. There was no comparison group. Imperial Bioscience, a company, is listed as the funder (Avcil et al., 2020).
Shin 2024 (human, placebo-controlled, split-face). Twenty-four healthy subjects had an active patch near one eye and a hyaluronic acid placebo patch near the other for 28 days. The active patch combined acetyl octapeptide-3, L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid. The authors reported better eye-wrinkle scores and lower water loss than placebo. They are affiliated with Raphas Co., Ltd. (Shin et al., 2024).
Both products combined several actives, so neither study shows what acetyl octapeptide-3 does alone. Both were small and linked to industry.
What safety data exist?
We found no Cosmetic Ingredient Review (CIR) safety assessment for acetyl octapeptide-3. CIR’s quick reference table, September 2020 edition, does not list it (CIR, 2020). Searches of the CIR website and PubMed found no later report. CosIng links no opinion from the EU Scientific Committee on Consumer Safety (SCCS).
In the patch studies, Avcil reported that no subject had primary or cumulative skin reactions. Shin reported no adverse effects. Both studies were small and short. Five of the six authors of a 2026 review work for Procter & Gamble. They argue that safety review of cosmetic peptides “must also evolve” (Bjerke et al., 2026).
What is acetyl octapeptide-3’s regulatory status, and how is it used in research?
Acetyl octapeptide-3 is a cosmetic ingredient, not an FDA-approved drug. FDA states that cosmetic products and ingredients, except color additives, “do not need FDA premarket approval” (FDA, 2025). The law defines cosmetics by intended use, such as “beautifying, promoting attractiveness, or altering the appearance.” Products meant to treat or prevent disease are drugs (FDA, 2024).
Congress enacted the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) on December 29, 2022 (FDA, 2026). It requires facility registration, product listing, serious adverse event reports within 15 business days, and safety records (FDA MoCRA page). In the EU, CosIng lists acetyl octapeptide-3 as an active entry.
In published research, acetyl octapeptide-3 appears as one active among several in cosmetic test products, as in the two patch studies above. We found no peer-reviewed laboratory study that tested the peptide alone.
Frequently asked questions about acetyl octapeptide-3
Is acetyl octapeptide-3 the same as SNAP-8?
Yes, in practice. SNAP-8 is the trade name, and the 2020 Errante review gives SNAP-8 the same sequence PubChem lists for acetyl octapeptide-3.
How is acetyl octapeptide-3 related to Argireline?
Its first six amino acids match acetyl hexapeptide-8 (Argireline). It adds alanine and aspartic acid at the end.
Is acetyl octapeptide-3 a peptide?
Yes. It is eight amino acids joined by peptide bonds, with an acetyl group at the start and an amide at the end.
Is acetyl octapeptide-3 FDA-approved?
No. It is a cosmetic ingredient. US cosmetic ingredients, other than color additives, do not need FDA premarket approval.
Has acetyl octapeptide-3 been tested alone in people?
Not in any peer-reviewed study we found. The two human studies tested patches that also contained other actives.
What to know now
- Identity: INCI name acetyl octapeptide-3; trade name SNAP-8; eight amino acids; 1,075.2 g/mol.
- Relation: the Argireline sequence plus alanine and aspartic acid.
- CosIng functions: humectant and skin conditioning.
- Mechanism: proposed SNAP-25 mimic, based mainly on manufacturer data.
- Evidence: two small, industry-linked human studies of multi-ingredient patches.
- Status: cosmetic ingredient; no CIR assessment found; not an FDA-approved drug.
What we’re watching
FDA’s ongoing MoCRA rollout, tracked on its MoCRA page, last updated October 29, 2026. Any CIR review of acetyl octapeptide-3, which would appear on cir-safety.org. Related guides: Argireline, dipeptide diaminobutyroyl benzylamide diacetate and pentapeptide-18.